About Scott Antonia
Pleural and Lung Cancer
Excellence in Research
20+ Years of Experience
Works for Specialty Center
Since his appointment in February 2019, Antonia has focused on developing an elite immunotherapy program at Duke to better treat diseases such as lung cancer and malignant pleural mesothelioma.
Immunotherapy involves finding more effective ways to use a patient’s own immune system in the fight against cancer.
For years, Antonia has been recognized as a world leader and pioneer in the transition of cancer therapeutics.
Antonia joined Duke Cancer Institute after more than two decades at the Moffitt Cancer Center in Tampa, Florida, including the previous seven years as chairman of the Department of Thoracic Oncology.
Treating and Researching Mesothelioma
At Moffitt, Antonia spearheaded the creation of the Mesothelioma Research and Treatment Center, which focused on the rare and aggressive cancer caused by asbestos.
He was recognized as Physician of the Year in 2005, Mentor of the Year in 2008 and Researcher of the Year in 2018 at Moffitt.
Antonia was the lead author of a study published by the New England Journal of Medicine in 2019 that detailed the effectiveness of Imfinzi (durvalumab) when combined with chemotherapy to treat non-small cell lung cancer.
Another study in 2019 proved the effectiveness of Opdivo, also known as nivolumab, as a long-term benefit for lung cancer. Cure Today and Medscape both published the study.
“Our principle motivation is to develop new therapies for unresectable tumors,” Antonia said. “Cancer treatment in general looks more promising now than ever before, but we can’t stop now.”
As a clinician, Antonia also has been credited with developing better collaboration between the basic research scientists and the clinical researchers, accelerating therapeutic advances.
Immunotherapy Tumor Vaccines
At Moffitt, Antonia’s research program included novel T-cell therapies and tumor vaccines in combination with immunotherapy strategies.
He has vast experience in developing clinical trials that have consistently advanced cancer treatment.
Antonia earned a Ph.D. and his medical degree from the University of Connecticut. He completed a residency in internal medicine and a fellowship in medical oncology from Yale University.
He also received a post-doctoral fellowship in immunobiology from the Yale University School of Medicine.
His work with lung cancer played a role in developing guidelines adopted and published by the National Comprehensive Cancer Network.
Disclaimer: Dr. Scott Antonia has no professional affiliation with Asbestos.com.
3 Cited Article Sources
Kahl, K. (2019, April 3). Pooled Analysis Shows Long-Term Benefit with Opdivo in Non-Small Cell Lung Cancer.
Retrieved from: https://www.curetoday.com/articles/pooled-analysis-shows-long-term-benefit-with-opdivo-in-non-small-cell-lung-cancer
Duke Cancer Institute. (2019, February 22). Antonio Appointed Director of DCI Center for Cancer Immunotherapy.
Retrieved from: https://dukecancerinstitute.org/news/antonia-appointed-director-dci-center-cancer-immunotherapy
- Duke Cancer Institute. (n.d.). Antonia, Scott Joseph. Retrieved from: https://dukecancerinstitute.org/member/antonia-scott-joseph
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified July 3, 2019